WRBY Stock Analysis: Warby Parker | NYSE
Medical Instruments & Supplies | NYSE, USA | Market Cap: 3.203m USD | 12M Return: 15.6% | US93403J1060 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 68.7M
Qual. Beats: 0
Rev. Trend: 99.8%
Qual. Beats: -1
Warnings
Tailwinds
No distinct edge detected
Seasonality 5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Warby Parker Inc. (NYSE: WRBY) is a U.S.-based eyewear retailer that sells prescription and non-prescription glasses, sunglasses, contact lenses, and related accessories. Founded in 2009 and headquartered in New York, the company operates a direct-to-consumer model through its e-commerce platform, mobile apps, and brick-and-mortar stores, serving customers in the U.S. and Canada. Warby Parker also provides eye exams and vision tests, positioning itself as a vertically integrated optical care provider.
As a mid-cap stock in the Consumer Discretionary sector (GICS Sub Industry: Other Specialty Retail), Warby Parker has been public since its September 2021 IPO. The company competes in the specialty retail space against traditional optical chains and online rivals, and its vertically integrated approach-combining product design, manufacturing, retail, and optical services-reflects a broader industry trend toward vertical integration in consumer brands seeking to capture more of the value chain.
- Active customer growth fuels e-commerce revenue expansion
- Retail store openings lift revenue but pressure near-term margins
- EssilorLuxottica and Zenni competition pressures pricing and market share
| Net Income: 7.74m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -4.65 > 1.0 |
| NWC/Revenue: 22.75% < 20% (prev 25.64%; Δ -2.89% < -1%) |
| CFO/TA 0.12 > 3% & CFO 95.4m > Net Income 7.74m |
| Net Debt (-41.7m) to EBITDA (63.4m): -0.66 < 3 |
| Current Ratio: 2.27 > 1.5 & < 3 |
| Outstanding Shares: last quarter (125.7m) vs 12m ago 2.60% < -2% |
| Gross Margin: 54.68% > 18% (prev 54.49%; Δ 0.19% > 0.5%) |
| Asset Turnover: 123.7% > 50% (prev 117.0%; Δ 6.66% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.27 (Total Current Assets 370.8m - Total Current Liabilities 163.5m) / Total Assets 772.3m |
| B: -0.88 (Retained Earnings -677.8m / Total Assets 772.3m) |
| C: 0.01 (EBIT TTM 9.91m / Avg Total Assets 737.1m) |
| D: 1.03 (Book Value of Equity 392.0m / Total Liabilities 380.3m) |
| Altman-Z'' = 0.07 = B |
| DSRI: 1.65 (Receivables 2.08m/1.14m, Revenue 911.6m/821.3m) |
| GMI: 1.00 (GM 54.49% / 54.68%) |
| AQI: 1.44 (AQ_t 0.02 / AQ_t-1 0.01) |
| SGI: 1.11 (Revenue 911.6m / 821.3m) |
| TATA: -0.11 (NI 7.74m - CFO 95.4m) / TA 772.3m) |
| Beneish M = -2.17 (Cap -4..+1) = BB |
As of October 29, 2026, the stock is trading at USD 24.43 with a total of 2,034,816 shares traded. Over the past week, the price has changed by -4.68%, over one month by -0.93%, over three months by -6.04% and over the past year by +15.62%.
Current recommended Stop Loss: 22.10 (which is 9.5% or 1.6 ATR below the current price).
Warby Parker has received a consensus analysts rating of 4.38. Therefore, it is recommended to buy WRBY.
- StrongBuy: 8
- Buy: 2
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 31 | 26.9% |
P/E Trailing = 431.8333
P/E Forward = 51.8135
P/S = 3.5132
P/B = 8.9212
Revenue TTM = 911.6m USD
EBIT TTM = 9.91m USD
EBITDA TTM = 63.4m USD
Long Term Debt = 215.4m USD (estimated: total debt 251.0m - short term 35.5m)
Short Term Debt = 35.5m USD (from shortTermDebt, last quarter)
Debt = 251.0m USD (from shortLongTermDebtTotal, last quarter) (leases 251.0m already included)
Net Debt = -41.7m USD (calculated: Debt 251.0m - CCE 292.7m)
Enterprise Value = 3.16b USD (3.20b + Debt 251.0m - CCE 292.7m)
Interest Coverage Ratio = unknown (Ebit TTM 9.91m / Interest Expense TTM 0.0)
EV/FCF = 145.4x (Enterprise Value 3.16b / FCF TTM 21.7m)
FCF Yield = 0.69% (FCF TTM 21.7m / Enterprise Value 3.16b)
FCF Margin = 2.39% (FCF TTM 21.7m / Revenue TTM 911.6m)
Net Margin = 0.85% (Net Income TTM 7.74m / Revenue TTM 911.6m)
Gross Margin = 54.68% ((Revenue TTM 911.6m - Cost of Revenue TTM 413.1m) / Revenue TTM)
Gross Margin QoQ = 57.94% (prev 54.05%)
Tobins Q-Ratio = 4.09 (Enterprise Value 3.16b / Total Assets 772.3m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 251.0m)
Taxrate = 21.85% (2.17m / 9.91m)
NOPAT = 7.74m (EBIT 9.91m * (1 - 21.85%))
Current Ratio = 2.27 (Total Current Assets 370.8m / Total Current Liabilities 163.5m)
Debt / Equity = 0.64 (Debt 251.0m / totalStockholderEquity, last quarter 392.0m)
Debt / EBITDA = -0.66 (Net Debt -41.7m / EBITDA 63.4m)
Debt / FCF = -1.92 (Net Debt -41.7m / FCF TTM 21.7m)
Total Stockholder Equity = 376.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 1.05% (Net Income 7.74m / Total Assets 772.3m)
RoE = 2.06% (Net Income TTM 7.74m / Total Stockholder Equity 376.3m)
RoCE = 1.67% (EBIT 9.91m / Capital Employed (Equity 376.3m + L.T.Debt 215.4m))
RoIC = 1.29% (NOPAT 7.74m / Invested Capital 598.8m)
WACC = 9.88% (E(3.20b)/V(3.45b) * Re(10.65%) + D(251.0m)/V(3.45b) * Rd(0.0%) * (1-Tc(0.22)))
Discount Rate = 10.65% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 91.09 | Cagr: 2.43%
[DCF] Terminal Value 67.61% ; FCFF base≈34.0m ; Y1≈29.8m ; Y5≈24.1m
[DCF] Fair Price = 3.24 (EV 309.1m - Net Debt -41.7m = Equity 350.8m / Shares 108.2m; r=9.88% [WACC]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: 99.80 | Revenue CAGR: 13.31% | SUE: -1.15 | # QB: -1
EPS current Quarter (2026-09-30): EPS=0.09 | Chg30d=+0.00% | Revisions=+0% | Analysts=9
EPS current Year (2026-12-31): EPS=0.42 | Chg30d=+0.00% | Revisions=-12% | GrowthEPS=+97.2% | GrowthRev=+11.2%
EPS next Year (2027-12-31): EPS=0.61 | Chg30d=+0.00% | Revisions=-57% | GrowthEPS=+46.6% | GrowthRev=+16.9%
[Analyst] Revisions Ratio: -42% (up=2, down=7)